scholarly journals Fe3O4 Nanoparticles for Complex Targeted Delivery and Boron Neutron Capture Therapy

Nanomaterials ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. 494 ◽  
Author(s):  
Kanat Dukenbayev ◽  
Ilya Korolkov ◽  
Daria Tishkevich ◽  
Artem Kozlovskiy ◽  
Sergey Trukhanov ◽  
...  
Keyword(s):  
Mössbauer Spectroscopy ◽  
Boron Neutron Capture Therapy ◽  
Fe3o4 Nanoparticles ◽  
Neutron Capture ◽  
Mossbauer Spectroscopy ◽  
Neutron Capture Therapy ◽  
X Ray ◽  
Mößbauer Spectroscopy ◽  
Boron Neutron Capture ◽  
Fe3o4 Nps

Magnetic Fe3O4 nanoparticles (NPs) and their surface modification with therapeutic substances are of great interest, especially drug delivery for cancer therapy, including boron-neutron capture therapy (BNCT). In this paper, we present the results of boron-rich compound (carborane borate) attachment to previously aminated by (3-aminopropyl)-trimethoxysilane (APTMS) iron oxide NPs. Fourier transform infrared spectroscopy with Attenuated total reflectance accessory (ATR-FTIR) and energy-dispersive X-ray analysis confirmed the change of the element content of NPs after modification and formation of new bonds between Fe3O4 NPs and the attached molecules. Transmission (TEM) and scanning electron microscopy (SEM) showed Fe3O4 NPs’ average size of 18.9 nm. Phase parameters were studied by powder X-ray diffraction (XRD), and the magnetic behavior of Fe3O4 NPs was elucidated by Mössbauer spectroscopy. The colloidal and chemical stability of NPs was studied using simulated body fluid (phosphate buffer—PBS). Modified NPs have shown excellent stability in PBS (pH = 7.4), characterized by XRD, Mössbauer spectroscopy, and dynamic light scattering (DLS). Biocompatibility was evaluated in-vitro using cultured mouse embryonic fibroblasts (MEFs). The results show us an increasing of IC50 from 0.110 mg/mL for Fe3O4 NPs to 0.405 mg/mL for Fe3O4-Carborane NPs. The obtained data confirm the biocompatibility and stability of synthesized NPs and the potential to use them in BNCT.

The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

2011 ◽  
Vol 69 (12) ◽  
pp. 1817-1818 ◽  
Author(s):  
T. Yamamoto ◽  
K. Nakai ◽  
T. Nariai ◽  
H. Kumada ◽  
T. Okumura ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
X Ray ◽  
Boron Neutron Capture ◽  
The Status

Accelerator-driven boron neutron capture therapy

2014 ◽  
Vol 29 (14) ◽  
pp. 1441004 ◽  
Author(s):  
Rob Edgecock
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
State Of The Art ◽  
Technical Problem ◽  
Hospital Environment ◽  
Neutron Capture Therapy ◽  
X Ray ◽  
Boron Neutron Capture ◽  
Uptake Process ◽  
Cancerous Cells

Boron Neutron Capture Therapy is a binary treatment for certain types of cancer. It works by loading the cancerous cells with a boron-10 carrying compound. This isotope has a large cross-section for thermal neutrons, the reaction producing a lithium nucleus and alpha particle that kill the cell in which they are produced. Recent studies of the boron carrier compound indicate that the uptake process works best in particularly aggressive cancers. Most studied is glioblastoma multiforme and a trial using a combination of BNCT and X-ray radiotherapy has shown an increase of nearly a factor of two in mean survival over the state of the art. However, the main technical problem with BNCT remains producing a sufficient flux of neutrons for a reasonable treatment duration in a hospital environment. This paper discusses this issue.

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Nucleophilic radiosynthesis of boron neutron capture therapy-oriented PET probe [18F]FBPA using aryldiboron precursors

2021 ◽  
Author(s):  
Jing He ◽  
Heng Yan ◽  
Yanrong Du ◽  
Yan Ji ◽  
Fei Cai ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

A reliable copper-mediated nucleophilic radiosynthesis of the BNCT-oriented PET probe [18F]FBPA was developed using novel aryldiboron precursors.

scholarly journals Optimized beam shaping assembly for a 2.1-MeV proton-accelerator-based neutron source for boron neutron capture therapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Pablo Torres-Sánchez ◽  
Ignacio Porras ◽  
Nataliya Ramos-Chernenko ◽  
Fernando Arias de Saavedra ◽  
Javier Praena
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Beam Shaping ◽  
Proton Accelerator ◽  
Neutron Capture Therapy ◽  
Beam Shape ◽  
New Era ◽  
Boron Neutron Capture ◽  
Optimal Beam ◽  
Beam Shaping Assembly

AbstractBoron Neutron Capture Therapy (BNCT) is facing a new era where different projects based on accelerators instead of reactors are under development. The new facilities can be placed at hospitals and will increase the number of clinical trials. The therapeutic effect of BNCT can be improved if a optimized epithermal neutron spectrum is obtained, for which the beam shape assembly is a key ingredient. In this paper we propose an optimal beam shaping assembly suited for an affordable low energy accelerator. The beam obtained with the device proposed accomplishes all the IAEA recommendations for proton energies between 2.0 and 2.1 MeV. In addition, there is an overall improvement of the figures of merit with respect to BNCT facilities and previous proposals of new accelerator-based facilities.

Sign in / Sign up

Export Citation Format

Share Document